View Document Preview and Link Document Date: 2009-03-31 11:11:49 Open Document File Size: 76,94 KB Share Result on Facebook
City Ann Arbor / / Company Pfizer / Merck Research Laboratories / Allergan Inc. / / / Facility Laboratory Sciences / University of North Carolina / Chapel Hill / Indiana University / Laboratory of Experimental Pathology / / / IndustryTerm chemical development / marketed drug products / chemicals / / MedicalCondition Endothelial Cell Tumors / tumor / neoplasms / Liver hemangiosarcoma / hemangiosarcoma/angiosarcoma / hemangiosarcoma / current issues / insulin resistance / hepatic hemangiosarcoma / liver hemangiosarcomas / hemangiosarcomas / tumors / rodent tumor / i.e.hemangioma/angioma / chronic treatment / aggressive / malignant tumor / Carcinogenesis / hemangiosarcoma incidence / hemangiosarcoma induction / chronic exposure / spontaneous hemangiosarcoma / Hemangiosarcoma / p53 tumor / single tumor / endothelial neoplasms / non-genotoxic carcinogenesis / hemangiosarcoma response / carcinomas / PPAR-mediated tumor / PPAR-Induced Rodent Tumors / malignant vascular tumors / II diabetes / sarcomatous tumors / / Organization Food and Drug Administration / Indiana University / Indianapolis / Laboratory of Experimental Pathology / University of North Carolina / Chapel Hill / US National Cancer Institute / / Person Role / David G. Pegg / Pres Type / Richard D. Storer / Brian G. Short / Jeri El-Hage / James E. Klaunig / David E. Malarkey / James A. Swenberg / / / Position Co-chair / CHAIR / / Technology gene expression / / SocialTag 
CONTROL ID: [removed]PRESENTATION TYPE: Symposium Secondary Pres Type - Proposal: Symposium IAT/ITS Designation: TITLE: Mode of Action Associated with Induction of Endothelial Cell Tumors - Hemangiosarcoma